The potential benefit of the mTOR-inhibitors, temsirolimus and everolimus, has been demonstrated only for a subset of bladder cancer patients, and use of these drugs has been associated with severe, not well-tolerated, adverse events [3,4]. The gene discussed is MTOR; the disease is urinary bladder cancer.